FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $5,189,638 | -24.1% | 1,090,260 | -9.1% | 0.01% | -33.3% |
| Q1 2023 | $6,835,674 | +56244.2% | 1,199,241 | -0.3% | 0.01% | -50.0% |
| Q4 2022 | $12,132 | -100.0% | 1,202,355 | -44.1% | 0.02% | -74.6% |
| Q3 2022 | $48,188,000 | -7.5% | 2,150,276 | +2.3% | 0.07% | -1.4% |
| Q2 2022 | $52,092,000 | -1.1% | 2,102,161 | +54.7% | 0.07% | +20.0% |
| Q1 2022 | $52,674,000 | -36.2% | 1,358,636 | -3.7% | 0.06% | -26.8% |
| Q4 2021 | $82,578,000 | +45.9% | 1,411,341 | +47.8% | 0.08% | +32.3% |
| Q3 2021 | $56,611,000 | – | 955,137 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $34,095 | 9.92% |
| Redmile Group, LLC | 12,957,222 | $130,738,370 | 5.35% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $10,465,913 | 2.67% |
| Casdin Capital, LLC | 2,050,000 | $20,684,500 | 1.60% |
| DAFNA Capital Management LLC | 550,940 | $5,558,985 | 1.57% |
| Artal Group S.A. | 2,600,000 | $26,234 | 1.46% |
| Monaco Asset Management SAM | 250,000 | $2,522,500 | 0.76% |
| Parametrica Management Ltd | 32,254 | $325,443 | 0.67% |
| Boxer Capital, LLC | 1,250,000 | $12,612,500 | 0.66% |
| Bellevue Group AG | 4,861,279 | $49,050,305 | 0.65% |